Enterprise Value
235.4M
Cash
197.2M
Avg Qtr Burn
-21.23M
Short % of Float
9.00%
Insider Ownership
5.72%
Institutional Own.
69.67%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Atacicept Details Lupus nephritis | Phase 3 Data readout | |
Atacicept (Origin) Details IgA nephropathy | Phase 2b Data readout | |
MAU868 Details Kidney transplantation, BK virus | Phase 2b Update |